| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,176 | 0,217 | 07.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Notice of Extraordinary General Meeting 2026 in Qlife Holding AB | 2 | Cision News | ||
| 26.01. | QLife Holding AB: Qlife submits Egoo PHE home testing system for regulatory approval | 324 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, today announces that the Company has formally submitted its Egoo PHE home-testing system for regulatory approval... ► Artikel lesen | |
| 22.01. | QLife Holding AB: Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7 | 74 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 19.01. | QLIFE HOLDING AB: Qlife prepares for pharmacy testing in Nordic markets | 1 | Cision News | ||
| QLIFE Aktie jetzt für 0€ handeln | |||||
| 15.01. | QLife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships | 110 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co., Ltd. ("Hipro"), announces a major milestone: the Egoo HbA1c... ► Artikel lesen | |
| 23.12.25 | QLife Holding AB: Qlife provides end-year operational update on key issues | 492 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets | 161 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an exclusive commercial agreement with Hipro Biotechnology Co.... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established | 233 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd.... ► Artikel lesen | |
| 12.12.25 | QLife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China | 205 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a groundbreaking project launched by Hipro Biotechnology Co.... ► Artikel lesen | |
| 05.12.25 | QLife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch | 138 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The... ► Artikel lesen | |
| 14.11.25 | QLife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued | 250 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025.... ► Artikel lesen | |
| 12.11.25 | Qlife Holding AB Q3 Sales Decline | 1 | RTTNews | ||
| 12.11.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q3, July - September 2025 | 141 | GlobeNewswire (Europe) | Advancing Integration & Innovation: Building a Diagnostics Powerhouse
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary... ► Artikel lesen | |
| 05.10.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended | 110 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The... ► Artikel lesen | |
| 22.09.25 | Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 | 1 | Cision News | ||
| 15.09.25 | QLife Holding AB: Qlife announces additional product line and progresses two new tests into clinical trials | 165 | GlobeNewswire (Europe) | Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests-nt-proBNP and potassium-into clinical trials targeting Congestive... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q2, April to June 2025 | 255 | GlobeNewswire (Europe) | Towards a merger with a vision
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - second quarter 2025
Revenue... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: Progress update on the reverse takeover process between Qlife and Hipro | 194 | GlobeNewswire (Europe) | Gothenburg, Sweden - Qlife Holding AB ("Qlife" or the "Company") and Hipro Biotechnology Co., Ltd. ("Hipro") remain fully committed to completing the transaction announced in the Letter of Intent signed... ► Artikel lesen | |
| 21.08.25 | Qlife Holding AB increases existing credit facility and extends the maturity date | 1 | Cision News | ||
| 21.08.25 | QLIFE HOLDING AB: Qlife together with Birmingham Women's and Children's NHS Foundation Trust achieve positive results for its rare disease self-test PHE product | 2 | Cision News |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | Märkte am Morgen: Gold, Silber, Bitcoin, Amgen, Alphabet, AMD, SAP, Siemens Healthineers, BASF | Das Umfeld an den Aktienmärkten ist aktuell alles andere als einfach. Das hat sich gestern mal wieder deutlich gezeigt. Der DAX geriet nach guten Start unter Druck und schloss 0,72 Prozent tiefer bei... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | DAX-Check LIVE: Fresenius Medical Care, Nordex, Puma, Sartorius Vz., Schaeffler, Siltronic im Fokus | Ein kurzzeitiger Ausverkauf bei Gold und Silber hat den DAX zum Wochenstart zunächst belastet. Die Unsicherheit beruhigte sich jedoch im Tagesverlauf, auch unterstützt durch eine Erholung an den US-Märkten.... ► Artikel lesen | |
| FRESENIUS | 49,760 | +1,06 % | Fresenius: 2026 setzt sich das Wachstum fort | Am 25. Februar wird Fresenius Zahlen zum vierten Quartal publizieren. Die Analysten der DZ Bank rechnen mit einer soliden Entwicklung. Wachstumsinvestitionen bei Kabi dürften sich bei den Margen bemerkbar... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | Hims & Hers-Aktie -10%: Warum profitiert sie nicht? | Die Hims & Hers-Aktie schoss am gestrigen Donnerstag kurzfristig um über +10% in die Höhe, beendete den Handelstag dann aber doch mit einem Minus von fast -4%. Am Freitagmorgen bricht der Kurs der Gesundheitsplattform... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |